KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EBIT: 2009-2024

Historic EBIT for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to -$76.3 million.

  • Arbutus Biopharma's EBIT rose 59.61% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.8 million, marking a year-over-year increase of 43.70%. This contributed to the annual value of -$76.3 million for FY2024, which is 2.28% up from last year.
  • According to the latest figures from FY2024, Arbutus Biopharma's EBIT is -$76.3 million, which was up 2.28% from -$78.1 million recorded in FY2023.
  • In the past 5 years, Arbutus Biopharma's EBIT registered a high of -$57.8 million during FY2020, and its lowest value of -$78.1 million during FY2023.
  • For the 3-year period, Arbutus Biopharma's EBIT averaged around -$73.3 million, with its median value being -$76.3 million (2024).
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 59.83% in 2020, then decreased by 27.19% in 2021.
  • Over the past 5 years, Arbutus Biopharma's EBIT (Yearly) stood at -$57.8 million in 2020, then fell by 27.19% to -$73.5 million in 2021, then rose by 10.97% to -$65.5 million in 2022, then decreased by 19.32% to -$78.1 million in 2023, then climbed by 2.28% to -$76.3 million in 2024.